Morgan Stanley Begins Coverage of Generate Biomedicines Inc with Overweight Rating and $20 Target Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy GENB?
Source: moomoo
Company Overview: Generate Biomedicines is a biotechnology company focused on developing protein-based therapeutics using its proprietary platform.
Recent Developments: The company has initiated coverage with an overweight rating, indicating positive expectations for its future performance.
Target Price: Analysts have set a target price of $20 for Generate Biomedicines, suggesting potential growth in its stock value.
Market Position: Generate Biomedicines aims to leverage its innovative technology to address unmet medical needs in various therapeutic areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GENB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GENB
Wall Street analysts forecast GENB stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.510
Low
Averages
High
Current: 11.510
Low
Averages
High
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ARK Genomic Revolution ETF Underperforms
- ETF Performance: The ARK Genomic Revolution ETF is down approximately 5.7% in Friday afternoon trading, indicating a weak performance that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Among the ETF's weakest components are Personalis, which fell about 12.2%, and Generate Biomedicines, down about 11.2%, suggesting increasing challenges in the biotech sector that may heighten investor concerns.
- Market Reaction: The negative performance of the ARK Genomic Revolution ETF has elicited strong reactions from investors, potentially prompting a reevaluation of valuations for related biotech companies, which could impact their future financing and growth plans.
- Industry Outlook: As market confidence in the biotech sector wanes, the performance of the ARK Genomic Revolution ETF may drive investors to reconsider their diversification strategies to mitigate risks and seek more stable returns.
See More
IPO Market Faces Delays Amid Volatility
- Market Volatility Impact: The IPO market faced significant volatility in Q1 2026 due to tech sell-offs, tariff turmoil, private credit issues, and the war in the Middle East, which grounded new issuance before it could take off.
- Decline in IPO Count: The quarter ended with 34 IPOs raising a total of $9.9 billion, reflecting a notable decrease in deal count compared to previous periods, indicating that market uncertainty is suppressing new issuances.
- Support from Large Offerings: Among the 34 IPOs, 22 raised over $100 million, including Forgent, an electrical equipment maker that raised over $1 billion, demonstrating ongoing investor appetite for larger transactions despite overall market challenges.
- Increased Valuation Pressure: The previous year's tech IPO revival faded as valuation multiples collapsed amid fears of disruption from AI, yet investors still showed some interest in new offerings, highlighting a complex market sentiment.
See More
Morgan Stanley Begins Coverage of Generate Biomedicines Inc with Overweight Rating and $20 Target Price
Company Overview: Generate Biomedicines is a biotechnology company focused on developing protein-based therapeutics using its proprietary platform.
Recent Developments: The company has initiated coverage with an overweight rating, indicating positive expectations for its future performance.
Target Price: Analysts have set a target price of $20 for Generate Biomedicines, suggesting potential growth in its stock value.
Market Position: Generate Biomedicines aims to leverage its innovative technology to address unmet medical needs in various therapeutic areas.
See More
Analysts Initiate Coverage on Generate Biomedicines with Strong Upside Potential
- Analyst Ratings Optimistic: Guggenheim and Piper Sandler have initiated coverage of Generate Biomedicines (GENB) with buy and outperform ratings, respectively, with Guggenheim setting a price target of $30, indicating approximately 140% upside based on the March 23 close.
- Innovative Platform Advantage: Piper Sandler's Edward Tenthoff highlighted Generate's platform as a 'protein discovery engine' that integrates powerful AI/ML algorithms with high-speed protein synthesis, showcasing its technological leadership in the biopharmaceutical sector.
- Clinical Trial Progress: Generate is conducting two phase 3 trials for the anti-thymic stromal lymphopoietin antibody GB-0895 for severe asthma, while gearing up to initiate phase I studies of MMAE neutralizer GB-4362, indicating its proactive approach in oncology treatments.
- Market Potential Assessment: Guggenheim's Seamus Fernandez expressed optimism about GB-0895, noting its biannual dosing, with a modeled 70% success probability in asthma and 40% in COPD, leading to projected global peak risk-adjusted sales of approximately $3.5 billion and $1 billion, respectively.
See More
Key Wall Street Rating Updates from Tuesday
- Apple Services Strength: Evercore ISI reiterates Apple as outperform based on a survey of 3,500 smartphone users indicating continued strength in Apple Services like Apple TV, with both engagement and monetization trending higher, suggesting enhanced competitiveness in its services ecosystem.
- Ralph Lauren Brand Elevation: Citi upgrades Ralph Lauren from neutral to buy, citing management's brand elevation efforts that have driven strong performance, with a projected 6.5% sales CAGR and over 350bps EBIT margin expansion by FY26, indicating significant long-term growth potential.
- Ecolab Investment Opportunity: JPMorgan upgrades Ecolab from neutral to overweight, noting that the stock has declined since February 27 amid rising Middle East tensions, while the broader market is down 4%, suggesting a buying opportunity for investors anticipating a rebound.
- AI Infrastructure Market Outlook: Bank of America initiates coverage of Nebius Group with a buy rating and a $150 price target, highlighting the company's differentiated offering in the rapidly growing AI Infrastructure-as-a-Service market, expected to benefit from sustained demand for AI computing.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
ARK Genomic Revolution ETF Underperforms
- ETF Performance: The ARK Genomic Revolution ETF is down approximately 5.7% in Friday afternoon trading, indicating a weak performance that could undermine investor confidence and lead to capital outflows.
- Stock Underperformance: Among the ETF's weakest components are Personalis, which fell about 12.2%, and Generate Biomedicines, down about 11.2%, suggesting increasing challenges in the biotech sector that may heighten investor concerns.
- Market Reaction: The negative performance of the ARK Genomic Revolution ETF has elicited strong reactions from investors, potentially prompting a reevaluation of valuations for related biotech companies, which could impact their future financing and growth plans.
- Industry Outlook: As market confidence in the biotech sector wanes, the performance of the ARK Genomic Revolution ETF may drive investors to reconsider their diversification strategies to mitigate risks and seek more stable returns.
See More
IPO Market Faces Delays Amid Volatility
- Market Volatility Impact: The IPO market faced significant volatility in Q1 2026 due to tech sell-offs, tariff turmoil, private credit issues, and the war in the Middle East, which grounded new issuance before it could take off.
- Decline in IPO Count: The quarter ended with 34 IPOs raising a total of $9.9 billion, reflecting a notable decrease in deal count compared to previous periods, indicating that market uncertainty is suppressing new issuances.
- Support from Large Offerings: Among the 34 IPOs, 22 raised over $100 million, including Forgent, an electrical equipment maker that raised over $1 billion, demonstrating ongoing investor appetite for larger transactions despite overall market challenges.
- Increased Valuation Pressure: The previous year's tech IPO revival faded as valuation multiples collapsed amid fears of disruption from AI, yet investors still showed some interest in new offerings, highlighting a complex market sentiment.
See More
Morgan Stanley Begins Coverage of Generate Biomedicines Inc with Overweight Rating and $20 Target Price
Company Overview: Generate Biomedicines is a biotechnology company focused on developing protein-based therapeutics using its proprietary platform.
Recent Developments: The company has initiated coverage with an overweight rating, indicating positive expectations for its future performance.
Target Price: Analysts have set a target price of $20 for Generate Biomedicines, suggesting potential growth in its stock value.
Market Position: Generate Biomedicines aims to leverage its innovative technology to address unmet medical needs in various therapeutic areas.
See More
Analysts Initiate Coverage on Generate Biomedicines with Strong Upside Potential
- Analyst Ratings Optimistic: Guggenheim and Piper Sandler have initiated coverage of Generate Biomedicines (GENB) with buy and outperform ratings, respectively, with Guggenheim setting a price target of $30, indicating approximately 140% upside based on the March 23 close.
- Innovative Platform Advantage: Piper Sandler's Edward Tenthoff highlighted Generate's platform as a 'protein discovery engine' that integrates powerful AI/ML algorithms with high-speed protein synthesis, showcasing its technological leadership in the biopharmaceutical sector.
- Clinical Trial Progress: Generate is conducting two phase 3 trials for the anti-thymic stromal lymphopoietin antibody GB-0895 for severe asthma, while gearing up to initiate phase I studies of MMAE neutralizer GB-4362, indicating its proactive approach in oncology treatments.
- Market Potential Assessment: Guggenheim's Seamus Fernandez expressed optimism about GB-0895, noting its biannual dosing, with a modeled 70% success probability in asthma and 40% in COPD, leading to projected global peak risk-adjusted sales of approximately $3.5 billion and $1 billion, respectively.
See More
Key Wall Street Rating Updates from Tuesday
- Apple Services Strength: Evercore ISI reiterates Apple as outperform based on a survey of 3,500 smartphone users indicating continued strength in Apple Services like Apple TV, with both engagement and monetization trending higher, suggesting enhanced competitiveness in its services ecosystem.
- Ralph Lauren Brand Elevation: Citi upgrades Ralph Lauren from neutral to buy, citing management's brand elevation efforts that have driven strong performance, with a projected 6.5% sales CAGR and over 350bps EBIT margin expansion by FY26, indicating significant long-term growth potential.
- Ecolab Investment Opportunity: JPMorgan upgrades Ecolab from neutral to overweight, noting that the stock has declined since February 27 amid rising Middle East tensions, while the broader market is down 4%, suggesting a buying opportunity for investors anticipating a rebound.
- AI Infrastructure Market Outlook: Bank of America initiates coverage of Nebius Group with a buy rating and a $150 price target, highlighting the company's differentiated offering in the rapidly growing AI Infrastructure-as-a-Service market, expected to benefit from sustained demand for AI computing.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
